Clinical Trial Update: Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of irinotecan and carmustine for patients with recurrent primary malignant glioma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• BiCNU (carmustine)
• Camptosar (irinotecan)

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED